Q-omics provides the consensus-scored NUP210 profile across patient tissues and cancer cell-line models. NUP210 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NUP210 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, NUP210 protein abundance shows 25,722 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, BLCA, and UCEC as cancer lineages where NUP210 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP210 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP210 survival associations across molecular data types. NUP210 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP210 RNA expression–survival associations across cancer types. High NUP210 expression shows unfavorable associations in MESO, LIHC, THCA, KIRP and LAML, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NUP210 RNA expression.
This table summarizes NUP210 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for NUP210. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP210 shows higher tumor expression in BLCA, COAD, LUAD, LIHC, KIRP and STAD. The BLCA box plot shows higher NUP210 RNA expression in tumor versus normal tissue (log2 FC = +1.917, t-test p < 0.001).
This table shows molecular features associated with NUP210 in patient tissues and cancer cell lines. In patient samples, NUP210 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, NUP210 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
